Latest News and Press Releases

STOCKHOLM, Sweden, Sept. 8, 2003 (PRIMEZONE) -- Amgen Inc. (Nasdaq:AMGN) and Biovitrum AB today announced that they have signed a multifaceted agreement under which Amgen receives exclusive rights to...

STOCKHOLM, Sweden, May 22, 2003 (PRIMEZONE) -- Biovitrum AB today announced that Biovitrum and GlaxoSmithKline (Other OTC:GLAXF) have jointly decided to focus their efforts on the development of...

STOCKHOLM, Sweden, April 7, 2003 (PRIMEZONE) -- Biovitrum today announced the start of a clinical Phase IIb study of the anti-obesity compound BVT.933 (GW876167), a 5-HT2C receptor agonist for the...

STOCKHOLM, Sweden, March 25, 2003 (PRIMEZONE) -- Biovitrum today announced the initiation of a Phase II clinical trial of BVT.3498, its lead compound for type 2 diabetes. Safety, tolerability and...

STOCKHOLM, Sweden, March 25, 2003 (PRIMEZONE) -- Biovitrum today announced the initiation of a Phase II clinical trial of BVT.3498, its lead compound for type 2 diabetes. Safety, tolerability and...

STOCKHOLM, Sweden, Jan. 14, 2003 (PRIMEZONE) -- Biovitrum AB today announced a commission agreement with the Danish pharmaceutical company Lundbeck A/S for the production of a protein...

LONDON and STOCKHOLM, Sweden, Oct. 23, 2002 (PRIMEZONE) -- GlaxoSmithKline plc (NYSE:GSK) ("GSK") and Biovitrum AB, today announced that they have signed a worldwide agreement to develop and...

STOCKHOLM, Sweden, and SITTINGBOURNE, U.K., Sept. 12, 2002 (PRIMEZONE) -- Biovitrum, one of Europe's leading biotech companies, and BioFocus plc, the pioneering collaborative drug discovery company,...

STOCKHOLM, Sweden, Sept. 4, 2002 (PRIMEZONE) -- SwedenBIO is a new industry association that will work actively to promote the successful establishment of internationally competitive biotechnology...

STOCKHOLM, Sweden, July 30, 2002 (PRIMEZONE) -- Biovitrum today announced the formation of its Scientific Advisory Board. The Board will assist Biovitrum's management in the development of the...